BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061326
CREATED:20250321T130027Z
LAST-MODIFIED:20250321T130140Z
UID:40739-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:4th Targeted Radiopharmaceuticals Summit US
DESCRIPTION:As demand for radiopharmaceuticals rises\, the industry is focused on strengthening isotope supply\, improving patient access\, and accelerating therapeutic development. \n \nJoin us at the 4th Targeted Radiopharmaceuticals Summit US in San Diego this July for the premier platform dedicated to radiopharmaceutical therapeutics and theranostics\, featuring: \n\n50+ Expert Speakers from leading biotech\, pharma\, and research institutions\, including Ratio Tx\, Abdera\, Alpha-9\nOncology\, Novartis\, AstraZeneca\, UCLA\, UCSF\, and more\n275+ Industry Attendees driving advancements from bench to bedside\n11+ Hours of Networking with top professionals\n3 Dedicated Tracks: Discovery & Preclinical\, Translational & Clinical\, and Clinical & Supply Chain\, curated to address key challenges\n\nOffering a tightly focused agenda dedicated to industry-specific topics\, this event is designed to advance approvals and commercialization. \nExplore critical areas such as isotope supply\, clinical development\, regulatory clarity\, novel molecule design\, investment and funding and much more. \nDon’t miss this essential event for anyone involved in the radiopharmaceuticals space! \nView the exclusive program here.
URL:http://www.pharmajournalist.com/event/4th-targeted-radiopharmaceuticals-summit-us/
LOCATION:The Hyatt Regency La Jolla\, 3777 La Jolla Village Drive\, San Diego\, CA\, 92122\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061326
CREATED:20250516T043336Z
LAST-MODIFIED:20250516T043336Z
UID:41089-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:Operationalize: Expanded Access Programs Summit West
DESCRIPTION:The Operationalize: Expanded Access Programs Summit West is coming to San Francisco! (July 29-31). \nFollowing the successful Boston and London meetings\, the Operationalize Expanded Access Programs Summit West is uniting stakeholders executing Early Access\, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need. \nThis Summit is the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies! \nFind out more at our website: https://ter.li/9ft05e. \nJoin 60+ experts\, from Eli Lilly\, Gilead\, Ultragenyx\, Daiichi Sankyo and more for three jam-packed days in San Francisco this July. Get exclusive insights\, real-world case studies and cutting-edge strategies to supercharge your Expanded Access Programs.
URL:http://www.pharmajournalist.com/event/operationalize-expanded-access-programs-summit-west/
LOCATION:The Clift Royal Sonesta\, 495 Geary Street\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061326
CREATED:20250520T095035Z
LAST-MODIFIED:20250520T095035Z
UID:41125-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:5th Fc-Mediated Function Summit
DESCRIPTION:The landscape of Fc-mediated therapies is undergoing a radical transformation\, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification. \nThis year\, we’re evaluating the cutting-edge of Fc biology and engineering\, diving deep into the game-changing potential of novel Fc modifications\, bispecific formats\, and targeted effector functions to revolutionize the treatment of cancer\, autoimmune diseases\, and beyond. Hear from the titans of the pharmaceutical industry\, including AbbVie\, Novartis\, and UCB as well as innovative biotechs including Seismic Therapeutics\, Paradigm Immunotherapies\, and many more – as they share their groundbreaking research and strategies for developing more effective\, safer\, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky\, and the pressure is on to continue this success and develop best-in-class treatments. \nWhy Attend? \n\nNavigate the latest insights into Fc receptor interactions and unlock the potential of precisely engineered antibodies for targeted efficacy and enhanced safety profiles\nConfront the challenges in therapeutic antibody development head-on by exploring novel Fc engineering strategies and optimizing treatment outcomes across diverse disease indications\nHear from 22+ industry luminaries and thought leaders\, including Sally Ward and Richard Blumberg\, and a multitude of companies who are pushing the boundaries of antibody engineering and Fc-mediated therapeutics\, including Argenx\, UCB\, and Boehringer Ingelheim\n\nDon’t miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function\, forge crucial collaborations\, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it! \nRegister now.
URL:http://www.pharmajournalist.com/event/5th-fc-mediated-function-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T061326
CREATED:20250613T092615Z
LAST-MODIFIED:20250613T092615Z
UID:41264-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:5th Next Generation Gene Therapy Vectors Summit
DESCRIPTION:The 5th Next Generation Gene Therapy Vectors Summit \n \nRecent announcements from major pharmaceutical companies scaling back their AAV gene therapy pipelines have raised concerns across the field. However\, this is not the end. It is an opportunity to reset\, refocus\, and rise to the challenge. While issues such as liver toxicity\, pre-existing antibodies\, and high manufacturing costs remain significant\, so too does the unmatched potential of AAV vectors. From their ability to cross the blood-brain barrier to delivering single-stranded DNA for single-dose cures\, AAV continues to offer enormous therapeutic promise. \nThe 5th Next Generation Gene Therapy Vectors Summit returns to Boston this September to spotlight the scientists and leaders who are continuing to innovate in vector design. This meeting is designed for those who understand that strategic setbacks can often pave the way for transformative breakthroughs\, as we saw in the early development of ADCs. \nOver the course of 3 days\, the summit will bring together experts in vector engineering\, translational science\, and clinical development to explore how the field can advance in a more refined and resilient direction. Attendees will hear from thought leaders such as Daniel Cohen (Spark Therapeutics)\, Eric Kelsic (Dyno Therapeutics)\, Jorge Santiago-Ortiz (Apertura Gene Therapy)\, Lolita Petit (Coave Therapeutics)\, Ralf Schmid (Novartis)\, and Roxanne Croze (4D Molecular Therapeutics). \nThe program will explore the latest innovations in capsid engineering\, novel strategies to overcome immune responses\, scalable systemic delivery technologies\, and key clinical insights that can shape future development pipelines. \nWhether your focus is vector optimization\, CMC\, or clinical translation\, this summit provides a valuable opportunity to connect with the experts and technologies leading the next phase of gene therapy innovation. Join the community in Boston this July and help shape a safer\, smarter\, and more successful future for AAV. \nFind Out More Here: https://ter.li/8qkdsh
URL:http://www.pharmajournalist.com/event/5th-next-generation-gene-therapy-vectors-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR